Insulin glulisine in the management of diabetes

References

• The Diabetes Control and Complications Trial (DCCT) Research GroupThe effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitusN Engl J Med1993329149779868366922
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) GroupIntensive blood-glucose control with sulphonylureas of insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33)Lancet199835291318378539742976
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) GroupEffect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS34)Lancet199835291318548659742977
   PubMed Web of Science ®Google Scholar
• The Action to Control Cardiovascular Risk in Diabetes Study GroupEffects of intensive glucose lowering in type 2 diabetesN Engl J Med2008358242545255918539917
   PubMed Web of Science ®Google Scholar
• The ADVANCE Collaborative GroupIntensive blood glucose control and vascular outcomes in patients with type 2 diabetesN Engl J Med2008358242560257218539916
   PubMed Web of Science ®Google Scholar
• DuckworthWAbrairaCMoritzTGlucose control and vascular complications in veterans with type 2 diabetesN Engl J Med2009360212913919092145
   PubMed Web of Science ®Google Scholar
• MaedlerKDonathMYBeta-cells in type 2 diabetes: a loss of function and massHorm Res200462Suppl 3S67S73
   Google Scholar
• ZimmetPAlbertiKGMMShawJGlobal and societal implications of the diabetes epidemicNature2001414686578278711742409
   PubMed Web of Science ®Google Scholar
• BrangeJOwensDRKangSVolundAMonomeric insulins and their experimental and clinical implicationsDiabetes Care19901399239542226110
   PubMed Web of Science ®Google Scholar
• WildeMIMcTavishDInsulin lispro: a review of its pharmacological properties and therapeutic use in the management of diabetes mellitusDrugs19975445976149339963
   PubMed Web of Science ®Google Scholar
• LindholmAJacobsenLVClinical pharmacokinetics and pharmacodynamics of insulin aspartClin Pharmacokinet200140964165911605714
   PubMed Web of Science ®Google Scholar
• BeckerRHFrickADClinical pharmacokinetics and pharmacodynamics of insulin glulisineClin Pharmacokinet200847172018076215
   PubMed Web of Science ®Google Scholar
• BeckerRHInsulin glulisine complementing basal insulins: a review of structure and activityDiabetes Technol Ther20079110912117316105
   PubMed Web of Science ®Google Scholar
• BeckerRHFrickADBurgerFPotgieterJHScholtzHInsulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjectsExp Clin Endocrinol Diabetes2005113843544316151977
   PubMed Web of Science ®Google Scholar
• HeiseTNosekLSpitzerHInsulin glulisine: a faster onset of action compared with insulin lisproDiabetes Obes Metab20079574675317593235
   PubMed Web of Science ®Google Scholar
• LuzioSPeterRDunseathGJMustafaLOwensDRA comparison of preprandial insulin glulisine versus insulin lispro in people with type 2 diabetes over a 12-h periodDiabetes Res Clin Pract200879226927518164094
   PubMed Web of Science ®Google Scholar
• HomkoCDeluzioAJimenezCKolaczynskiJWBodenGComparison of insulin aspart and lisproDiabetes Care20032672027203112832307
   PubMed Web of Science ®Google Scholar
• HorvathKBockGRegittnigWInsulin glulisine, insulin lispro and regular human insulin chow comparable end-organ metabolic effects: an exploratory studyDiabetes Obes Metab200810648449117764465
   PubMed Web of Science ®Google Scholar
• SiebenhoferAPlankJBergholdAShort acting insulin analogues versus regular human insulin in patients with diabetes mellitusCochrane Database Syst Rev2006192CD00328716625575
   PubMedGoogle Scholar
• GargSKRosenstockJWaysKOptimized basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with basal insulin glargineEndocr Pract2005111111716033730
   PubMedGoogle Scholar
• DaileyGRosenstockJMosesRGWaysKInsulin glulisine provides improved glycemic control in patients with type 2 diabetesDiabetes Care200427102363236815451901
   PubMed Web of Science ®Google Scholar
• DreyerMPragerRRobinsonAEfficacy and safety of insulin glulisine in patients with type 1 diabetesHorm Metab Res2005371170270716308840
   PubMed Web of Science ®Google Scholar
• HoogmaRPLSchumickiDSafety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetesHorm Metab Res200638642943316823727
   PubMed Web of Science ®Google Scholar
• JohanssonUBAdamsonUCLinsPEWredlingRAImproved blood glucose variability, HbA1c insuman infusat and less insulin requirement in IDDM patients using insulin lispro in CSII. The Swedish Multicenter lispro insulin studyDiabetes Metab200026319219610880892
   PubMed Web of Science ®Google Scholar
• GaleEAA randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with type 1 diabetes on intensified insulin therapyDiabet Med200017320921410784225
   PubMed Web of Science ®Google Scholar
• FergusonSCStrachanMWJanesJMFrierBMSevere hypoglycaemia in patients with type 1 diabetes and impaired awareness of hypoglycaemia: a comparative study of insulin lispro and regular human insulinDiabetes Metab Res Rev200117428529111544612
   PubMed Web of Science ®Google Scholar
• RennerRPfutznerATrautmannMHarzerOSauterKLandgrafRUse of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trialDiabetes Care199922578478810332682
   PubMed Web of Science ®Google Scholar
• HomePDLindholmARiisAInsulin aspart vs human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: a randomized controlled trialDiabet Med2000171176277011131100
   PubMed Web of Science ®Google Scholar
• BottUEbrahimSHirschbergerSSkovlundSEEffect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with type 1 diabetesDiabet Med200320862663412873289
   PubMed Web of Science ®Google Scholar
• AnnuzziGDel PratoSArcariRPreprandial combination of lispro and NPH insulin improves overall blood glucose control in type 1 diabetic patients: a multicenter randomized crossover trialNutr Metab Carciovasc Dis2001113168175
   Web of Science ®Google Scholar
• OttesenJLNilssonPJamiJThe potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse modelDiabetologia19943712117811857895946
   PubMed Web of Science ®Google Scholar
• FinebergNSFinebergSEAndersonJHBirkettMAGibsonRGHufferdSImmunologic effects of insulin lispro [(Lys(B28), Pro(B29) human insulin)] in IDDM and NIDDM patients previously treated with insulinDiabetes19964512175017548922361
   PubMed Web of Science ®Google Scholar
• FinebergSEHuangJBrunelleRGulliyaKSAndersonJH JrEffect of long-term exposure to insulin lispro on the induction of antibody response in patients with type 1 or type 2 diabetesDiabetes Care2003261899612502663
   PubMed Web of Science ®Google Scholar
• LindholmAJensenLBHomePDRaskinPBoehmBORastamJImmune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetesDiabetes Care200222587688211978684
   PubMed Web of Science ®Google Scholar